KIDNEY CANCER DRUGS MARKET ANALYSIS

Kidney Cancer Drugs Market Size and Trends

The kidney cancer drugs market is estimated to be valued at USD 6.89 billion in 2024 and is expected to reach USD 10.31 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031. Rising prevalence of kidney cancer worldwide owing to changing lifestyles and growing geriatric population are the major factors driving the demand for effective treatment drugs.

To learn more about this report, Request sample copy

The market is witnessing positive growth owing to increasing demand for targeted drugs for kidney cancer treatment. Many pipeline drugs are under development which would provide better efficacy and reduced side effects. As these drugs receive regulatory approvals, they would capture significant market share and substitute existing approved drugs. Moreover, rising awareness about early diagnosis and treatment availability is further projected to aid market growth during the forecast period.

Rising Prevalence of Risk Factors

The increasing prevalence of risk factors for kidney cancer such as obesity, hypertension, and smoking is expected to significantly drive the market growth. Kidney cancer risk is strongly associated with obesity, with overweight and obese individuals having up to twice the risk of developing the disease compared to those with a healthy weight. With obesity rates rising sharply all over the world, more people are becoming vulnerable to kidney cancer. For instance, over 70% of American adults are either overweight or obese currently according to government data. This translates to a huge population at high risk. For example, according to the American Society of Clinical Oncology (ASCO), in February 2022, kidney cancer was diagnosed in 79,000 persons in the U.S. in 2022 (50,290 males and 28,710 women). 2020 saw an estimated 431,288 cases of kidney cancer diagnosed globally. Kidney cancer is sixth among cancers that affect men in the U.S. For women, it ranks as the seventh most prevalent cancer. Kidney cancer patients are often diagnosed between the ages of 65 and 74, with an average diagnostic age of 64. According to the National Center for Biotechnology Information, almost 270,000 new instances of renal cell carcinoma (RCC) were diagnosed globally in 2018. RCC makes up around 4% of all adult malignancies.

To learn more about this report, Request sample copy

Targeted Therapy - A Revolution in Treatment

The development of targeted drug therapies in recent years has revolutionized the treatment of kidney cancer. These targeted drugs inhibit specific molecules involved in cancer cell growth and survival, proving much more effective than traditional chemotherapy drugs. A major breakthrough was the advent of tyrosine kinase inhibitors that block the vascular endothelial growth factor receptor pathway critical for tumor angiogenesis. Drugs like Sutent, Inlyta, and Cabometyx gained quick approvals and popularity due to their superior efficacy over chemotherapy. Immunotherapy is another breakthrough approach gaining widespread usage. Checkpoint inhibitors that help activate the immune system against cancer cells have significantly improved treatment outcomes for many types of advanced kidney cancer. Blockbuster drugs such as Opdivo and Keytruda are at the forefront of the immunotherapy revolution for kidney cancer treatment. Their ability to induce long lasting remissions even in late-stage patients is truly remarkable. With continuous advances being made in targeted therapies and newer immunotherapies in the pipeline, personalized medicine seems poised to take over as the dominant treatment paradigm. This fundamental shift to more effective drugs and longer durations of therapy will fuel significant growth in spending on kidney cancer medications.